DDInter336 DDInter1802
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Celecoxib {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Celecoxib {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Celecoxib {u} (Compound) causes {v} (Side Effect) Blood urine present
Blood urine present {u} (Side Effect) is caused by {v} (Compound) Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Celecoxib {u} (Compound) causes {v} (Side Effect) Haemorrhoidal haemorrhage
Haemorrhoidal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Lomitapide
Lomitapide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Celecoxib {u} (Compound) causes {v} (Side Effect) Cerebral haemorrhage
Cerebral haemorrhage {u} (Side Effect) is caused by {v} (Compound) Fingolimod
Fingolimod {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Celecoxib {u} (Compound) causes {v} (Side Effect) Haemorrhoidal haemorrhage
Haemorrhoidal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Apixaban
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Ticagrelor
Celecoxib {u} (Compound) binds {v} (Gene) CA14
CA14 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Celecoxib (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Celecoxib (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Celecoxib (Compound) causes Blood urine present (Side Effect) and Blood urine present (Side Effect) is caused by Aprepitant (Compound) and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Celecoxib (Compound) causes Haemorrhoidal haemorrhage (Side Effect) and Haemorrhoidal haemorrhage (Side Effect) is caused by Lomitapide (Compound) and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Celecoxib (Compound) causes Cerebral haemorrhage (Side Effect) and Cerebral haemorrhage (Side Effect) is caused by Fingolimod (Compound) and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Celecoxib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Celecoxib (Compound) causes Haemorrhoidal haemorrhage (Side Effect) and Haemorrhoidal haemorrhage (Side Effect) is caused by Apixaban (Compound) and Apixaban may lead to a major life threatening interaction when taken with Ticagrelor
Celecoxib (Compound) binds CA14 (Gene) and CA14 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor